Dear Readers, we are happy to share the most interesting legal and policy updates concerning health industry that we read today. We hope you enjoy reading it.
1. The Federation of Pharmaceutical Entrepreneurs (FOPE) has reportedly requested the National Pharmaceutical Pricing Authority (NPPA) to permit the 45 days period to revise Maximum Retail Prices for scheduled drugs and medical devices. A request for permitting the implementation a 10% prices increase for non-scheduled formulations upon completion of one year from last price revision, irrespective of the current GST rate revision.
Source: short-url.org/1fN2T
2. The National Accreditation Board for Testing and Calibration Laboratories (NABL) has issued a clarification emphasizing that its logo and symbol are exclusive to NABL. Accredited labs must adhere to NABL policies, ensuring proper use of accreditation symbols. Unauthorized use may lead to legal actions.
Source: short-url.org/1fN31
3. The Indian government aims to meet the WHO’s recommended doctor-patient ratio of 1:1000 by increasing the number of doctors uniformly across the country. Efforts include balancing the undergraduate to postgraduate medical education ratio and integrating skill-based and virtual learning to enhance healthcare quality.
Source: short-url.org/1fN39
4. MSME pharma associations have urged Health Ministry to ease the implementation timeline for tougher GMP (Good Manufacturing Practices) norms that are effective from 1 January 2026. They warn many small businesses may shut due to financial strain, lack of infrastructure and stringent deadlines.
Source: short-url.org/1fN3f
5. A new non-invasive test approved by the United States Food and Drug Administration to detect early signs of Alzheimer’s disease is now available in India. It uses a 15-minute cognitive assessment and advanced blood biomarker analysis, offering an Amyloid Probability Score. It is an alternative to invasive procedures like lumbar punctures.
Source: short-url.org/1fN3m